Andrew D. Huberman, PhD

Virtual reality on the horizon for treatment of glaucomaOne laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.
Early neuronal changes may be biomarkers for glaucomaA team of researchers may soon be able to catch glaucoma cases early by spotting nerve damage, said Andrew D. Huberman, PhD, as he provided an update on the work of the Glaucoma Research Foundation’s Catalyst for a Cure Biomarkers Initiative at the Glaucoma 360 New Horizons Forum.
Catalyst for a Cure team establishes targets for glaucoma biomarkersSeveral years ago, the Glaucoma Research Foundation (GRF) expanded its initiative to advance glaucoma research through a collaborative approach by creating a second Catalyst for a Cure research team.